Skip to main content
OpenTrials

Clinical trial condition

Metastatic Renal Cell Carcinoma

Explore clinical trials studying Metastatic Renal Cell Carcinoma. Study availability and eligibility vary by location and protocol.

126 public trials 24 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Renal Cell Carcinoma trial results

Completed

CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)

NCT02187302

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • University of California San Diego La Jolla, California, United States
  • David Geffen School of Medicine UCLA Los Angeles, California, United States
  • Cedars Sinai Medical Center Los Angeles, California, United States
  • Rocky Mountain Cancer Centers Denver, Colorado, United States
View all 43 locations
View Trial Details
Completed

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

NCT01550367

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Loyola University Chicago Maywood, Illinois, United States
  • Indiana University Simon Cancer Center Indianapolis, Indiana, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Dartmouth-Hitchcock Medical Center Hanover, New Hampshire, United States
View Trial Details
Completed

Testosterone in Metastatic Renal Cell Carcinoma Patients

NCT03379012

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • A.I. Kryzhanovsky Krasnoyarsk Cancer Center Krasnoyarsk, Russia
  • Kidney Cancer Research Bureau Moscow, Russia
  • RUDN University Moscow, Russia
  • City Clinical Oncology Center Saint Petersburg, Russia
View Trial Details
Completed

A Study for Participants With Metastatic Renal Cell Carcinoma

NCT00709995

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Vienna, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Villejuif, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Rome, Italy
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Warsaw, Poland
View Trial Details
Completed

Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma

NCT03519542

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela, A Coruña, Spain
  • Hospital Marqués de Valdecilla Santander, Cantabria, Spain
  • Hospital Universitario central de Asturias Oviedo, Principality of Asturias, Spain
  • Hospital Universitarios de Burgos Burgos, Spain
View Trial Details
Completed

PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

NCT01415167

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +24 more
Locations
  • The University of Arizona Cancer Center Tucson, Arizona, United States
  • Moores UCSD Cancer Center La Jolla, California, United States
  • USC Norris Cancer Center Los Angeles, California, United States
  • Southern California Permanente Medical Group Riverside, California, United States
View all 45 locations
View Trial Details
Completed

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

NCT01136733

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +14 more
Locations
  • Tucson, Arizona, United States
  • Orange, California, United States
  • San Diego, California, United States
  • Tampa, Florida, United States
View all 37 locations
View Trial Details

Related conditions